Skip to main content

HPV Infections

14
Pipeline Programs
3
Companies
10
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
4
0
7
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
3100%
+ 12 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Bovax Biotechnology
Bovax BiotechnologyChina - Chongqing
5 programs
1
3
2-doses Group among 9-14 yearsPhase 31 trial
9-valent HPV vaccinePhase 3Vaccine1 trial
Experimental: Experimental: 9-valent Human PapillomavirusPhase 31 trial
HPV vaccinePhase 1Vaccine1 trial
Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV VaccineN/AVaccine1 trial
Active Trials
NCT05371353Recruiting600Est. May 2027
NCT03085381Completed90Est. Aug 2018
NCT05027776Recruiting1,348Est. Sep 2026
+2 more trials
MSD
MSDIreland - Ballydine
5 programs
1
2
2
Quadrivalent Human PapillomavirusPhase 3
Quadrivalent Human PapillomavirusPhase 3
Quadrivalent Human PapillomavirusPhase 2
Quadrivalent Human PapillomavirusPhase 2
Quadrivalent Human PapillomavirusPhase 1
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
5 programs
1
2
2
Quadrivalent Human PapillomavirusPhase 31 trial
Quadrivalent Human PapillomavirusPhase 31 trial
Quadrivalent Human PapillomavirusPhase 21 trial
Quadrivalent Human PapillomavirusPhase 21 trial
Quadrivalent Human PapillomavirusPhase 11 trial
Active Trials
NCT00635830Completed40Est. Apr 2008
NCT00411749Completed107Est. Sep 2009
NCT00378560Completed1,021Est. Sep 2009
+2 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Bovax Biotechnology2-doses Group among 9-14 years
Bovax Biotechnology9-valent HPV vaccine
Bovax BiotechnologyExperimental: Experimental: 9-valent Human Papillomavirus
Sharp TherapeuticsQuadrivalent Human Papillomavirus
Sharp TherapeuticsQuadrivalent Human Papillomavirus
Sharp TherapeuticsQuadrivalent Human Papillomavirus
Sharp TherapeuticsQuadrivalent Human Papillomavirus
Bovax BiotechnologyHPV vaccine
Sharp TherapeuticsQuadrivalent Human Papillomavirus
Bovax BiotechnologyImmune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine

Clinical Trials (10)

Total enrollment: 8,612 patients across 10 trials

NCT05027776Bovax Biotechnology2-doses Group among 9-14 years

Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years

Start: Sep 2021Est. completion: Sep 20261,348 patients
Phase 3Recruiting
NCT04895020Bovax Biotechnology9-valent HPV vaccine

Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years

Start: May 2021Est. completion: May 20261,200 patients
Phase 3Recruiting
NCT05372016Bovax BiotechnologyExperimental: Experimental: 9-valent Human Papillomavirus

Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Start: Sep 2020Est. completion: Jun 20221,200 patients
Phase 3Completed
NCT00733122Sharp TherapeuticsQuadrivalent Human Papillomavirus

Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)

Start: Oct 2009Est. completion: Oct 20130
Phase 3Withdrawn
NCT00834106Sharp TherapeuticsQuadrivalent Human Papillomavirus

Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041)

Start: Dec 2008Est. completion: Sep 20163,006 patients
Phase 3Completed
NCT00411749Sharp TherapeuticsQuadrivalent Human Papillomavirus

V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)

Start: Dec 2006Est. completion: Sep 2009107 patients
Phase 2Completed
NCT00378560Sharp TherapeuticsQuadrivalent Human Papillomavirus

V501 Efficacy Study in Women Aged 18 to 26 (V501-027)

Start: Jun 2006Est. completion: Sep 20091,021 patients
Phase 2Completed
NCT03085381Bovax BiotechnologyHPV vaccine

A Phase I Study of Quadrivalent HPV Recombinant Vaccine

Start: Dec 2016Est. completion: Aug 201890 patients
Phase 1Completed
NCT00635830Sharp TherapeuticsQuadrivalent Human Papillomavirus

An Open-Label, Single Dose Safety Study of Quadrivalent HPV Vaccine in Chinese Female Subjects (V501-035)

Start: Mar 2008Est. completion: Apr 200840 patients
Phase 1Completed
NCT05371353Bovax BiotechnologyImmune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine

Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine

Start: May 2022Est. completion: May 2027600 patients
N/ARecruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

7 late-stage (Phase 3) programs, potential near-term approvals
3 actively recruiting trials targeting 8,612 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.